S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
General Mills Retreats To Buy Zone Ahead Of Earnings 
Penny Stock Shows Big Potential (Ad)
Is Fastenal Setting Up a Furious Flag Breakout?
UBS Buys Failing Credit Suisse: Will It Cause a Fed Pause?
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
General Mills Retreats To Buy Zone Ahead Of Earnings 
Penny Stock Shows Big Potential (Ad)
Is Fastenal Setting Up a Furious Flag Breakout?
UBS Buys Failing Credit Suisse: Will It Cause a Fed Pause?
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
General Mills Retreats To Buy Zone Ahead Of Earnings 
Penny Stock Shows Big Potential (Ad)
Is Fastenal Setting Up a Furious Flag Breakout?
UBS Buys Failing Credit Suisse: Will It Cause a Fed Pause?
S&P 500   3,951.57
DOW   32,244.58
QQQ   305.97
5 Tech Stocks With Bank-Like Dividend Yields
Penny Stock Shows Big Potential (Ad)
Mullen Automotive: Investment? No. Compelling Speculation, Yes 
First Republic Bank Hits New Low, Dimon Pushes for More Cash
Penny Stock Shows Big Potential (Ad)
GBTC: The One Place to Buy Bitcoin for 58 Cents on the Dollar
General Mills Retreats To Buy Zone Ahead Of Earnings 
Penny Stock Shows Big Potential (Ad)
Is Fastenal Setting Up a Furious Flag Breakout?
UBS Buys Failing Credit Suisse: Will It Cause a Fed Pause?
NASDAQ:SUPN

Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

$35.58
+0.65 (+1.86%)
(As of 03/20/2023 12:00 AM ET)
Add
Compare
Today's Range
$35.13
$35.79
50-Day Range
$34.93
$42.03
52-Week Range
$24.95
$42.09
Volume
381,819 shs
Average Volume
492,981 shs
Market Capitalization
$1.93 billion
P/E Ratio
34.54
Dividend Yield
N/A
Price Target
$47.00

Supernus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
32.1% Upside
$47.00 Price Target
Short Interest
Bearish
8.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
-0.10mentions of Supernus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$2.43 M Sold Last Quarter
Proj. Earnings Growth
145.45%
From $0.66 to $1.62 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.60 out of 5 stars

Medical Sector

84th out of 988 stocks

Pharmaceutical Preparations Industry

25th out of 482 stocks


SUPN stock logo

About Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Q4 2022 Supernus Pharmaceuticals Inc Earnings Call
Penny Stock Shows Big Potential
The $4.37 trillion wellness market and the little-known penny stock to get on radar now.
Supernus Enters Into $150 Million Credit Facility
SUPN Supernus Pharmaceuticals, Inc.
Supernus Pharma's Charts Are Looking Super
Supernus Announces Third Quarter 2022 Financial Results
Axsome Therapeutics: All Eyes On Auvelity Launch
See More Headlines
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Company Calendar

Last Earnings
2/28/2023
Today
3/21/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
575
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$47.00
High Stock Price Forecast
$47.00
Low Stock Price Forecast
$47.00
Forecasted Upside/Downside
+32.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$60.71 million
Pretax Margin
9.10%

Debt

Sales & Book Value

Annual Sales
$667.24 million
Cash Flow
$2.86 per share
Book Value
$16.39 per share

Miscellaneous

Free Float
49,646,000
Market Cap
$1.93 billion
Optionable
Optionable
Beta
1.01

Key Executives

  • Jack A. Khattar
    President, CEO, Secretary & Director
  • Timothy C. Dec
    Chief Financial Officer & Senior Vice President
  • Frank Mottola
    Senior VP-Quality, GMP Operations & IT
  • Padmanabh P. Bhatt
    Chief Scientific Officer & Senior Vice President
  • Jonathan Rubin
    Chief Medical Officer & Senior Vice President













SUPN Stock - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings
or view top-rated stocks.

What is Supernus Pharmaceuticals' stock price forecast for 2023?

1 Wall Street analysts have issued twelve-month target prices for Supernus Pharmaceuticals' stock. Their SUPN share price forecasts range from $47.00 to $47.00. On average, they predict the company's stock price to reach $47.00 in the next year. This suggests a possible upside of 32.1% from the stock's current price.
View analysts price targets for SUPN
or view top-rated stocks among Wall Street analysts.

How have SUPN shares performed in 2023?

Supernus Pharmaceuticals' stock was trading at $35.67 at the start of the year. Since then, SUPN shares have decreased by 0.3% and is now trading at $35.58.
View the best growth stocks for 2023 here
.

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our SUPN earnings forecast
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings data on Tuesday, February, 28th. The specialty pharmaceutical company reported $0.43 earnings per share for the quarter, missing the consensus estimate of $0.73 by $0.30. The specialty pharmaceutical company earned $167.33 million during the quarter, compared to analyst estimates of $180.38 million. Supernus Pharmaceuticals had a trailing twelve-month return on equity of 7.12% and a net margin of 9.10%. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.04 earnings per share.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $580.00 million-$620.00 million, compared to the consensus revenue estimate of $590.51 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (8.06%), Macquarie Group Ltd. (4.48%), Dimensional Fund Advisors LP (4.41%), Stephens Investment Management Group LLC (2.97%), GW&K Investment Management LLC (2.60%) and Renaissance Technologies LLC (2.33%). Insiders that own company stock include Frank Mottola, Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Padmanabh P Bhatt, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $35.58.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $1.93 billion and generates $667.24 million in revenue each year. The specialty pharmaceutical company earns $60.71 million in net income (profit) each year or $1.03 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

The company employs 575 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.

This page (NASDAQ:SUPN) was last updated on 3/21/2023 by MarketBeat.com Staff